Results 181 to 190 of about 137,392 (257)

Distinct Symptom Occurrence Subgroups Among Patients With Colorectal Cancer: Differences in Social Determinants of Health and Diet Quality

Research in Nursing &Health, EarlyView.
ABSTRACT Colorectal cancer (CRC) is a leading cause of cancer mortality in the United States. Many patients with CRC experience physical and psychological symptoms that diminish quality of life and are shaped by social determinants of health (SDOH) and diet quality.
Youran Lee, Qing Yang, Melissa Kay, Donald E. Bailey, Biljana Gigic, Sheetal Hardikar, Adetunji T. Toriola, David Shibata, Christopher I. Li, Doratha A. Byrd, Jane C. Figueiredo, Ildiko Strehli, Megan Mclaws, Vaia Florou, Mmadili Ilozumba, Patricia Erickson, Apurva Medhe, Cornelia M. Ulrich, Rosa M. Gonzalez‐Guarda   +18 more
wiley   +1 more source

A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis. [PDF]

Medicine (Baltimore)
Yang Q, Yan Y.
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Diverting Loop Ileostomy as an Alternative to Emergent Colectomy in Acute Severe Ulcerative Colitis Flare following Checkpoint-Inhibitor Therapy. [PDF]

Inflamm Bowel Dis
Tan EX, An V, Garg M.
europepmc   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment. [PDF]

Front Immunol
Yang Y, Zhu H.
europepmc   +1 more source

Associations of Circadian Clock Gene Variants with Clinical Features and Treatment Characteristics in Ulcerative Colitis. [PDF]

J Clin Med
Yildirim S, Tuncel FC, Herek C, Sahin M, Pehlivan S.   +4 more
europepmc   +1 more source

Characteristics, properties and limitations of per‐ or polyfluoroalkyl substances (PFASs) and fluoropolymers

Polymer International, EarlyView.
An overview and categorization of man‐made per‐ or polyfluoroalkyl substances (PFASs) including low‐molar‐mass and high‐molar‐mass fluorochemicals, and their international regulations is presented. Though certain PFASs are toxic, bioaccumulative and cross the human cellular membranes, others, such as fluoropolymers, are safe, reliable and involved in ...
Bruno Améduri
wiley   +1 more source

A Young Woman With Ulcerative Colitis Presenting With Facial Diplegia, a Variant of Guillain-Barré Syndrome. [PDF]

Am J Case Rep
Wei R, Zhang Z, Mu X, Zhou L.
europepmc   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source